GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Price-to-Owner-Earnings

Yumanity Therapeutics (FRA:8IY) Price-to-Owner-Earnings : (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-22), Yumanity Therapeutics's share price is €1.47. Yumanity Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Yumanity Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


FRA:8IY's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.52
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-22), Yumanity Therapeutics's share price is €1.47. Yumanity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was €-2.75. Therefore, Yumanity Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-22), Yumanity Therapeutics's share price is €1.47. Yumanity Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was €-2.75. Therefore, Yumanity Therapeutics's PE Ratio without NRI for today is At Loss.


Yumanity Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Yumanity Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Price-to-Owner-Earnings Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
Price-to-Owner-Earnings
- - -

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Yumanity Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Yumanity Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yumanity Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's Price-to-Owner-Earnings falls into.



Yumanity Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Yumanity Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.47/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yumanity Therapeutics  (FRA:8IY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Yumanity Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines